Patrick Leavey, M.D.

Interim Chief, Division of Pediatric Hematology and Oncology; Associate Vice Chair of Research Operations

  • Pediatrics - Hematology-Oncology
  • Sarcoma
  • Malignant Hematology


Patrick Leavey, M.D., graduated from the Royal College of Surgeons in Ireland in 1986. He spent 4 years in Ireland as a junior house officer (Internal Medicine and Pediatrics), 2 years at Princess Margaret Hospital in Perth, Western Australia as a pediatric registrar and then came to the US to do his pediatric hematology/oncology fellowship at The Children’s Hospital Denver and University of Colorado Health Sciences Center in 1992. Dr. Leavey worked in the lab of Daniel Ambruso, M.D. for 4 years on projects related to the influence of G-CSF on granulocyte function and the exploration and identification of a novel neutrophil cytosolic protein.

Dr. Leavey joined the pediatric faculty at UT Southwestern Medical Center in 1998 where he is currently a Professor of Pediatrics and a Pediatric Oncologist at Children’s Health, Children’s Medical Center Dallas and Plano.

During his years of training Dr. Leavey became a member of the Royal College of Physicians of Ireland, a Fellow of the Royal Australasian College of Physicians and a Diplomate of Child Health from the National University of Ireland. He was granted a Doctorate in Medicine from the National University of Ireland, based on his work in the Ambruso laboratory. He is subspecialty board certified in Pediatric Hematology/Oncology by the American Board of Pediatrics.

Currently Dr. Leavey holds several leadership positions both regionally and nationally. He is the Associate Vice Chair for Research Operations at the Department of Pediatrics, and the Associate Director for Clinical research for the Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center Dallas. Dr. Leave is the Immediate Past President of the Active Medical / Dental Staff at Children's Medical Center Dallas and past President of the American Society of Pediatric Hematology/Oncology. At the Children’s Oncology Group (COG), Dr. Leavey was a long-standing member of the Bone Sarcoma Steering Committee up to 2023. Dr. Leavey continues to serve on medical advisory boards for the Children’s Cancer Fund and The Clayton Dabney Foundation.

Dr. Leavey hold several key positions in clinical and translational research. He is the co-chair for the COG study AOST2031, a co-investigator for a CPRIT funded study of whole slide imaging in pediatric rhabdomyosarcoma and the principal investigator for a Team Connor Foundation award to study machine learning tools in osteosarcoma. Dr. Leavey is also the site PI for an American Society of Hematology Award, establishing the North Texas Sickle Cell Disease Clinical Trial Unit.

Education & Training
  • Medical School - Royal College of Surgeons (1980-1986)
  • Residency - Children's Hospital of Denver (1996-1998), Pediatrics
  • Fellowship - University of Colorado Health Sciences Center (1992-1996), Pediatric Hematology/oncology
  • Residency - St. Vincents Hospital - Dublin Ireland (1987-1989), Internal Medicine
  • Internship - Beaumont Hospital (1986-1987), General Surgery
Professional Associations & Affiliations
  • Dallas County Medical Society and Texas Medical Association
  • Connective Tissue Oncology Society
  • Children's Oncology Group (2002)
  • American Society of Pediatric Hematology/Oncology (2004)
  • Society for Pediatric Research (2006)
  • American Society of Clinical Oncology (2012)
Honors & Awards
  • D Magazine Best Pediatric Specialist, 2002, 2010-2011, 2013, 2015-2016, 2018-2022
  • Achievement Award 2005, ’Gift of Giving Back Award’ first such award given by the Clayton Dabney Foundation for Kids with Cancer
  • Elected to the Society for Pediatric Research 2006
  • Medical Achievement Award 2008, Little Mo Award - awarded by Wipe out Kids Cancer
  • Faculty Teaching Award 2009, UT Southwestern and Children's Medical Center
Books & Publications
  • Development of a novel biomarker for patients with Osteosarcoma
  • Development of sophisticated genetic and clinically annotated data for patients with sarcoma in Texas
  • Development of advances in therapy for patients with Ewing Sarcoma with an emphasis on protocol development for patients with newly diagnosed and recurrent Ewing Sarcoma

Clinical Focus

  • Sarcoma
  • Malignant Hematology
  • Medical Treatment of Blood Disorders (Hematology)
  • General Hematology/Oncology

See More

Results: 1 Locations